Category: Articles
The New York Times, December 7, 2021 (with Benjamin Mueller)
A report out of South Africa offered a first glimpse at how vaccinated people might fare against the fast-spreading Omicron variant of the coronavirus.
Laboratory experiments found that Omicron seems to dull the power of the Pfizer-BioNTech vaccine, but also hinted that people who have received a booster shot might be better protected.
Continue reading “Pfizer’s vaccine provides some protection against Omicron, a lab study suggests.”
The New York Times, December 7, 2021
As the world worries that the Omicron coronavirus variant may cause a surge of cases and weaken vaccines, drug developers have some encouraging news: Two new Covid-19 pills are coming soon, and are expected to work against all versions of the virus.
The Food and Drug Administration is expected to soon authorize a pill made by Merck and Ridgeback Biotherapeutics, called molnupiravir, which reduces the risk of hospitalization and death from Covid-19 by 30 percent if taken within five days of the onset of symptoms.
Continue reading “New Covid Pills Offer Hope as Omicron Looms”
The New York Times, December 5, 2021
People who received Pfizer-BioNTech vaccines may get as much benefit from a Johnson & Johnson booster shot as a Pfizer one. That’s the finding of a small study released on Sunday.
Researchers at the Beth Israel Deaconess Medical Center in Boston studied 65 people who had received two shots of the Pfizer vaccine. Six months after the second dose, the researchers gave 24 of the volunteers a third dose of the Pfizer vaccine and gave 41 the Johnson & Johnson shot. (The study was funded in part by Johnson & Johnson and has not yet been published in a scientific journal.)
The New York Times, December 2, 2021
People looking for a booster shot of a Covid-19 vaccine probably don’t need to fret about what brand it is: Many combinations of shots are likely to provide strong protection, according to a large new study.
In a comparison of seven different vaccine brands, British researchers found that most of them prompted a strong immune response, with the mRNA shots from Moderna and Pfizer-BioNTech eliciting the largest responses. The study was published on Thursday in The Lancet.
Continue reading “Most Covid Vaccines Will Work as Boosters, Study Suggests”
The New York Times, November 30, 2021 (with Rebecca Robbins)
A federal advisory committee on Tuesday voted to recommend that the government for the first time authorize the use of an antiviral pill to combat the worst effects of Covid-19.
The advisory committee, in a surprisingly narrow 13-to-10 vote, endorsed the pill from Merck, while public health officials worldwide raced to buttress their defenses against the newly emerging Omicron variant of the coronavirus.
The Merck treatment, known as molnupiravir, has been shown to modestly reduce the risk of hospitalization and death from Covid. The pill could be authorized for use in the United States within days and available to patients within weeks.
Continue reading “Merck’s Covid Treatment Pill Wins Blessing of F.D.A. Panel”